Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Convalescent plasma vs standard plasma Quality of life, · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs standard plasma Grades 3 and 4 adverse events · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | 1 study · 248 participants | Very low |
Summary of findings table ‐ Convalescent plasma vs standard plasma Serious adverse events · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 0.8 [0.55, 1.15] | 3 studies · 327 participants | Very low |
Summary of findings table ‐ Convalescent plasma vs human immunoglobulin All‐cause mortality at up to day 28 · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 1.07 [0.76, 1.5] | 1 study · 190 participants | Low |
Summary of findings table ‐ Convalescent plasma vs human immunoglobulin Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs human immunoglobulin Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs human immunoglobulin Quality of life ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs human immunoglobulin Grades 3 and 4 adverse events ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs human immunoglobulin Serious adverse events ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone All‐cause mortality at up to day 28 · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | OR 0.36 [0.09, 1.46] | 2 studies · 536 participants | Very low |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individualswith moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 1.03 [0.97, 1.11] | 6 studies · 14477 participants | High |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Admission to hospital or death within 28 days · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 1.05 [0.6, 1.84] | 1 study · 376 participants | Low |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Symptom resolution‐ all initial symptoms resolved ‐ not reported · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Time to symptom resolution (absolute effect calculated for day 12) · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | HR 1.05 [0.85, 1.3] | 1 study · 376 participants | Low |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Quality of life, · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Grades 3 and 4 adverse events · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 1.29 [0.75, 2.19] | 1 study · 376 participants | Low |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Serious adverse events · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 1.14 [0.66, 1.94] | 1 study · 376 participants | Low |
Summary of findings table ‐ Convalescent plasma vs standard plasma All‐cause mortality at up to day 28 · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | OR 0.3 [0.05, 1.75] | 2 studies · 1597 participants | Very low |
Summary of findings table ‐ Convalescent plasma vs standard plasma Admission to hospital or death within 28 days · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 0.49 [0.31, 0.75] | 2 studies · 1595 participants | Moderate |
Summary of findings table ‐ Convalescent plasma vs standard plasma Symptom resolution‐ all initial symptoms resolved · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 1.12 [0.98, 1.27] | 1 study · 416 participants | Low |
Summary of findings table ‐ Convalescent plasma vs standard plasma Time to symptom resolution ‐ not reported · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Clinical improvement: participants discharged from hospital · individualswith moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 1 [0.97, 1.02] | 6 studies · 12721 participants | High |
Summary of findings table ‐ Convalescent plasma vs standard plasma Quality of life, · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs standard plasma Grades 3 and 4 adverse events ‐ not reported · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs standard plasma Serious adverse events ‐ not reported · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Quality of life, · individualswith moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | 1 study · 483 participants | Low |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Grades 3 and 4 adverse events · individualswith moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 1.17 [0.96, 1.42] | 6 studies · 2392 participants | Low |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Serious adverse events ‐ total · individualswith moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 1.14 [0.91, 1.44] | 6 studies · 3901 participants | Moderate |
Summary of findings table ‐ Convalescent plasma vs standard plasma All‐cause mortality at up to day 28 · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 0.73 [0.45, 1.19] | 4 studies · 484 participants | Very low |
Summary of findings table ‐ Convalescent plasma vs standard plasma Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 5.59 [0.29, 108.38] | 1 study · 34 participants | Very low |
Summary of findings table ‐ Convalescent plasma vs standard plasma Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Remdesivir and standard care vs standard care (plus/minus placebo) All‐cause mortality at up to day 281 · hospitalised adults with moderate to severe COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | RR 0.93 [0.81, 1.06] | 4 studies · 7142 participants | Moderate |
Remdesivir and standard care vs standard care (plus/minus placebo) Clinical worsening: participants admitted to hospital or deceased at up to day 28 · non‐hospitalised adults with mild COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | RR 0.28 [0.11, 0.75] | 1 study · 562 participants | Moderate |
Remdesivir and standard care vs standard care (plus/minus placebo) Quality of life · non‐hospitalised adults with mild COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | no estimate extracted | NR | No studies |
Remdesivir and standard care vs standard care (plus/minus placebo) Serious adverse events at up to day 28 · non‐hospitalised adults with mild COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | RR 0.27 [0.1, 0.7] | 1 study · 562 participants | Low |
Remdesivir and standard care vs standard care (plus/minus placebo) Adverse events (any grade) at up to day 28 · non‐hospitalised adults with mild COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | RR 0.91 [0.76, 1.1] | 1 study · 562 participants | Moderate |
Remdesivir and standard care vs standard care (plus/minus placebo) All‐cause mortality at up to day 60 · hospitalised adults with moderate to severe COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | RR 0.85 [0.69, 1.05] | 1 study · 1281 participants | Moderate |
Remdesivir and standard care vs standard care (plus/minus placebo) In‐hospital mortality at up to day 150 · hospitalised adults with moderate to severe COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | RR 0.93 [0.84, 1.03] | 1 study · 8275 participants | Moderate |
Remdesivir and standard care vs standard care (plus/minus placebo) Clinical improvement: participants alive and ready to be discharged at up to day 282 · hospitalised adults with moderate to severe COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | RR 1.11 [1.06, 1.17] | 4 studies · 2514 participants | Moderate |
Remdesivir and standard care vs standard care (plus/minus placebo) Clinical worsening: time to new need for invasive mechanical ventilation or death within 28 days3 · hospitalised adults with moderate to severe COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | HR 0.67 [0.54, 0.82] | 2 studies · 1734 participants | Moderate |
Remdesivir and standard care vs standard care (plus/minus placebo) Adverse events (any grade) at up to day 28 · hospitalised adults with moderate to severe COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | RR 1.04 [0.92, 1.18] | 4 studies · 2498 participants | Low |
Remdesivir and standard care vs standard care (plus/minus placebo) Serious adverse events at up to day 28 · hospitalised adults with moderate to severe COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | RR 0.84 [0.65, 1.07] | 4 studies · 2498 participants | Low |
Remdesivir and standard care vs standard care (plus/minus placebo) All‐cause mortality at up to day 28 · non‐hospitalised adults with mild COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | no estimate extracted | 1 study · 562 participants | Ungraded |
Remdesivir and standard care vs standard care (plus/minus placebo) Clinical improvement: participants with symptom alleviation at up to day 14 · non‐hospitalised adults with mild COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | HR 1.41 [0.73, 2.71] | 1 study · 126 participants | Very low |
Intervention NR 28‐day all‐cause mortality · hospitalised adults with COVID‐19 (moderate to severe disease) Antiplatelet agents for the treatment of adults with COVID‐19 (2023) · Cochrane | RR 0.95 | 3 studies · 17249 participants | Moderate |
Intervention NR Quality of life up to longest · non‐hospitalised adults with mild COVID‐19 Antiplatelet agents for the treatment of adults with COVID‐19 (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Thrombotic events up to day 45 · non‐hospitalised adults with mild COVID‐19 Antiplatelet agents for the treatment of adults with COVID‐19 (2023) · Cochrane | Peto OR 0.37 [0.09, 1.46] | 2 studies · 4209 participants | Low |
Intervention NR Adverse events during study treatment · non‐hospitalised adults with mild COVID‐19 Antiplatelet agents for the treatment of adults with COVID‐19 (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious adverse events up to day 45 · non‐hospitalised adults with mild COVID‐19 Antiplatelet agents for the treatment of adults with COVID‐19 (2023) · Cochrane | Peto OR 1 [0.6, 1.64] | 1 study · 3881 participants | Low |
Intervention NR Major bleeding events up to longest · non‐hospitalised adults with mild COVID‐19 Antiplatelet agents for the treatment of adults with COVID‐19 (2023) · Cochrane | no estimate extracted | 1 study · 328 participants | Very low |